- Home
- IMMX vs SPCB Comparison
IMMX vs SPCB Comparison
Compare IMMX & SPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- SPCB
- Stock Information
- Founded
- IMMX 2014
- SPCB 1988
- Country
- IMMX United States
- SPCB Israel
- Employees
- IMMX N/A
- SPCB N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- SPCB Semiconductors
- Sector
- IMMX Health Care
- SPCB Technology
- Exchange
- IMMX Nasdaq
- SPCB Nasdaq
- Market Cap
- IMMX 61.1M
- SPCB 53.3M
- IPO Year
- IMMX 2021
- SPCB N/A
- Fundamental
- Price
- IMMX $2.65
- SPCB $8.68
- Analyst Decision
- IMMX Strong Buy
- SPCB Strong Buy
- Analyst Count
- IMMX 1
- SPCB 1
- Target Price
- IMMX $7.00
- SPCB $18.00
- AVG Volume (30 Days)
- IMMX 220.7K
- SPCB 90.9K
- Earning Date
- IMMX 08-11-2025
- SPCB 08-14-2025
- Dividend Yield
- IMMX N/A
- SPCB N/A
- EPS Growth
- IMMX N/A
- SPCB N/A
- EPS
- IMMX N/A
- SPCB 1.89
- Revenue
- IMMX N/A
- SPCB $27,831,000.00
- Revenue This Year
- IMMX N/A
- SPCB $2.73
- Revenue Next Year
- IMMX N/A
- SPCB $22.87
- P/E Ratio
- IMMX N/A
- SPCB $4.59
- Revenue Growth
- IMMX N/A
- SPCB 2.90
- 52 Week Low
- IMMX $1.26
- SPCB $2.55
- 52 Week High
- IMMX $3.20
- SPCB $18.95
- Technical
- Relative Strength Index (RSI)
- IMMX 49.64
- SPCB 35.88
- Support Level
- IMMX $2.63
- SPCB $9.00
- Resistance Level
- IMMX $3.20
- SPCB $9.59
- Average True Range (ATR)
- IMMX 0.22
- SPCB 0.51
- MACD
- IMMX -0.04
- SPCB -0.13
- Stochastic Oscillator
- IMMX 3.51
- SPCB 12.56
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About SPCB SuperCom Ltd. (Israel)
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.